Press the button and be introduced to a new random company!

Introduce me >

Social media

facebook   Follow us on Twitter

Coverage

Boule Diagnostics

Boule Diagnostics

Instruments and reagents for blood analysis

Boule Diagnostics is a Swedish diagnostics company that develops, manufactures and markets instruments and consumable products for blood diagnostics, specializing in blood cell counting (CBC) systems, in both human and veterinary hematology. Boule Diagnostics is a global company with approximately 170 employees located in Sweden, USA and Mexico and with a market presence via distributors in addition to its own sales and marketing organisation in more than 100 countries.

The main opportunity for Boule Diagnostics would be to gain market share in the global CBC market within hematology and/or broaden its product offering.

We note a number of risk factors for Boule Diagnostics, including market risk, competition, legal and regulatory risk, product development risk, and currency and macroeconomic risk.

SEKm 2020 2021e 2022e
Sales 400 472 560
Sales growth (%) -19,7 17,7 18,7
EBITDA 56 66 109
EBITDA margin (%) 13,9 14 19,4
EBIT adj 25 46 88
EBIT adj margin (%) 6,1 9,7 15,8
Pretax profit -49 40 86
EPS rep -2,47 1,29 3,42
EPS growth (%) -224,1 152,2 165,3
EPS adj 1,16 1,29 3,42
DPS 0,55 0,65 1
EV/EBITDA (x) 21 16,9 10,2
EV/EBIT adj (x) 47,8 24,3 12,6
P/E (x) -24,1 42,7 16,1
P/E adj (x) 51,4 42,7 16,1
EV/sales (x) 2,9 2,4 2
FCF yield (%) 3,3 1,8 4,4
Dividend yield (%) 0,9 1,2 1,8
Net IB debt/EBITDA 0,3 0,7 0,4
Lease adj. FCF yield (%) 2,3 0,7 3,4
Lease adj. ND/EBITDA -0,2 -0,1 0
SEKm 2020 2021e 2022e
Leasing payments -11 -12 0
Sales 400 472 560
COGS -223 -262 -298
Gross profit 177 209 262
Other operating items -121 -143 -153
EBITDA 56 66 109
Depreciation on tangibles -8 -8 -8
Depreciation on intangibles -4 -4 -4
EBITA 34 46 88
Goodwill impairment charges 0 0 0
Other impairment and amortisation -40 0 0
EBIT -6 46 88
Other financial items 0 0 0
Net financial items -43 -6 -2
Associated income 0 0 0
Other EO items 0 0 0
Pretax profit -49 40 86
Tax 1 -15 -20
Net profit -48 25 66
Minority interest 0 0 0
Net profit discontinued 0 0 0
Net profit to shareholders -48 25 66
EPS -2,47 1,29 3,42
EPS Adj 1,16 1,29 3,42
Total extraordinary items after tax -30,4 0 0
Tax rate (%) -2 -37,4 -23
Gross margin (%) 44,3 44,4 46,7
EBITDA margin (%) 13,9 14 19,4
EBITA margin (%) 8,5 9,7 15,8
EBIT margin (%) -1,5 9,7 15,8
Pretax margin (%) -12,2 8,5 15,4
Net margin (%) -12 5,3 11,9
Growth rates Y/Y 2020 2021 2022
Sales growth (%) -19,7 17,7 18,7
EBITDA growth (%) -39,7 18,1 64,6
EBIT growth (%) -108,2 880,1 93
Net profit growth (%) -224,1 152,2 165,3
EPS growth (%) -224,1 152,2 165,3
Profitability 2020 2021 2022
ROE (%) -15,9 8,9 20,8
ROE Adj (%) 7,5 8,9 20,8
ROCE (%) -1 14 23,4
ROCE Adj(%) 18,9 14 23,4
ROIC (%) -1,3 7 14,7
ROIC Adj (%) 5,5 7 14,7
Adj earnings numbers 2020 2021 2022
EBITDA Adj 86 66 109
EBITDA Adj margin (%) 21,5 14 19,4
EBITA Adj 65 46 88
EBITA Adj margin (%) 16,1 9,7 15,8
EBIT Adj 25 46 88
EBIT Adj margin (%) 6,1 9,7 15,8
Pretax profit Adj 21 40 86
Net profit Adj 22 25 66
Net profit to shareholders Adj 22 25 66
Net Adj margin (%) 5,6 5,3 11,9
Depreciation and amortisation -22 -20 -20
Of which leasing depreciation -10 -9 -9
EO items -30 0 0
Impairment and PPA amortisation -40 0 0
EBITDA lease Adj 75 54 109
EBITDA lease Adj margin (%) 18,8 11,5 19,4
SEKm 2020 2021e 2022e
EBITDA 56 66 109
Net financial items -43 -6 -2
Paid tax 1 -15 -20
Non-cash items 25 5 0
Cash flow before change in WC 38 50 87
Change in WC 37 -2 -20
Operating cash flow 75 47 66
CAPEX tangible fixed assets -7 -8 -9
CAPEX intangible fixed assets -30 -20 -10
Acquisitions and disposals 0 0 0
Free cash flow 38 19 47
Dividend paid 0 -11 -13
Share issues and buybacks 0 0 0
Other non cash items 20 -39 -22
Decrease in net IB debt 14 -16 -5
Balance Sheet (SEKm) 2020 2021 2022
Goodwill 73 77 77
Indefinite intangible assets 0 0 0
Definite intangible assets 116 152 179
Tangible fixed assets 20 17 16
Other fixed assets 100 115 128
Fixed assets 343 412 462
Inventories 55 50 50
Receivables 33 39 46
Other current assets 16 20 22
Cash and liquid assets 33 16 17
Total assets 480 538 598
Shareholders equity 269 292 345
Minority 0 0 0
Total equity 269 292 345
Long-term debt 2 5 5
Pension debt 3 3 3
Convertible debt 0 0 0
Deferred tax 16 16 16
Other long-term liabilities 77 77 77
Short-term debt 10 5 5
Accounts payable 29 34 41
Other current liabilities 36 53 53
Total liabilities and equity 480 538 598
Net IB debt 19 44 43
Net IB debt excl. pension debt 15 41 40
Capital invested 381 434 487
Working capital 38 22 25
EV breakdown 2020 2021 2022
Market cap. diluted (m) 1155 1068 1068
Net IB debt Adj 19 44 43
Market value of minority 0 0 0
Reversal of shares and participations 0 0 0
Reversal of conv. debt assumed equity 0 0 0
EV 1174 1112 1111
Capital efficiency (%) 2020 2021 2022
Total assets turnover (%) 75,1 92,7 98,5
Capital invested turnover (%) 92,3 115,1 118,8
Capital employed turnover (%) 113,2 136,3 139,9
Inventories / sales (%) 14 11,2 8,2
Customer advances / sales (%) 7,6 6,2 5,4
Payables / sales (%) 7,4 6,8 7,2
Working capital / sales (%) 11,2 6,3 4,2
Financial risk and debt service 2020 2021 2022
Net debt / equity (%) 6,9 15,2 12,5
Net debt / market cap (%) 1,6 4,2 4
Equity ratio (%) 56,1 54,3 57,7
Net IB debt adj. / equity (%) 6,9 15,2 12,5
Current ratio (%) 154,5 108 110,8
EBITDA / net interest (%) 129,7 1146,7 5427,6
Net IB debt / EBITDA (%) 33,1 67,3 39,6
Interest cover (%) 80,4 658,9 3848,2
Lease liability amortisation -11 -12 -12
Other intangible assets 116 165 196
Right-of-use asset 35 37 39
Total other fixed assets 100 117 134
Leasing liability 36 47 47
Total other long-term liabilities 93 98 98
Net IB debt excl. leasing -18 -3 -4
Net IB debt / EBITDA lease Adj (%) -23,4 -5,1 -3,8
SEKm 2020 2021e 2022e
Shares outstanding adj. 19 19 19
Fully diluted shares Adj 19 19 19
EPS -2,47 1,29 3,42
Dividend per share Adj 0,6 0,7 1
EPS Adj 1,16 1,29 3,42
BVPS 13,87 15,02 17,79
BVPS Adj 4,16 2,58 3,78
Net IB debt / share 1 2,3 2,2
Share price 60,69 55 55
Market cap. (m) 1178 1068 1068
Valuation 2020 2021 2022
P/E -24,1 42,7 16,1
EV/sales 2,93 2,36 1,99
EV/EBITDA 21 16,9 10,2
EV/EBITA 34,4 24,3 12,6
EV/EBIT -200,3 24,3 12,6
Dividend yield (%) 0,9 1,2 1,8
FCF yield (%) 3,3 1,8 4,4
P/BVPS 4,29 3,66 3,09
P/BVPS Adj 14,3 21,32 14,56
P/E Adj 51,4 42,7 16,1
EV/EBITDA Adj 13,6 16,9 10,2
EV/EBITA Adj 18,2 24,3 12,6
EV/EBIT Adj 47,8 24,3 12,6
EV/cap. employed 3,7 3,2 2,7
Investment ratios 2020 2021 2022
Capex / sales 9,2 5,9 3,4
Capex / depreciation 321 254,7 171,9
Capex tangibles / tangible fixed assets 35,4 46,9 55
Capex intangibles / definite intangibles 26 12,1 5,1
Depreciation on intangibles / definite intangibles 3,4 1,8 1,6
Depreciation on tangibles / tangibles 38,2 46,8 48,8
Lease adj. FCF yield (%) 2,3 0,7 3,4

Equity research

Read earlier research

Media

Boule Diagnostics - Company presentation with CEO Jesper Söderqvist
Boule Diagnostics - Company presentation with CEO Jesper Söderqvist

Main shareholders - Boule Diagnostics

Main shareholders Share capital % Voting shares % Verified
Svolder 12.4 % 12.4 % 31 Aug 2021
Martin Gren (Grenspecialisten) 11.7 % 11.7 % 30 Jun 2021
Thomas Eklund 10.1 % 10.1 % 30 Jun 2021
Swedbank Robur Fonder 10.0 % 10.0 % 31 Jul 2021
Nordea Fonder 8.9 % 8.9 % 31 Jul 2021
Tredje AP-fonden 8.4 % 8.4 % 30 Jun 2021
Keel Capital 4.3 % 4.3 % 30 Jun 2021
Länsförsäkringar Fonder 4.0 % 4.0 % 31 Aug 2021
Andra AP-fonden 3.5 % 3.5 % 30 Jun 2021
Norges Bank 2.0 % 2.0 % 30 Jun 2021
Source: Holdings by Modular Finance AB

Insider list - Boule Diagnostics

Name Quantity Code Date
Jesper Söderqvist + 878 BUY 12 Aug 2021
Jesper Söderqvist + 122 BUY 12 Aug 2021
Jesper Söderqvist + 1 000 BUY 12 Aug 2021
Gustaf Peter Reinhold von Ehrenheim + 20 000 BUY 18 Feb 2021
Gustaf Peter Reinhold von Ehrenheim + 12 125 BUY 17 Feb 2021
Gustaf Peter Reinhold von Ehrenheim + 7 875 BUY 11 Feb 2021
Mikael Ekholm + 10 000 BUY 19 Aug 2020
Jesper Söderqvist + 130 000 BUY 17 Aug 2020
Karin Helena Börjesson + 40 000 BUY 17 Aug 2020
Fredrik Ekdahl + 50 000 BUY 25 Sep 2019

Show More